Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 5014-5028

  Yen, Po Jen ^a,b   Herschhorn, Alon ^a   Haim, Hillel ^a   Salas, Ignacio ^a   Gu, Christopher ^a   Sodroski, Joseph ^a,b   Gabuzda, Dana ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY COMBINING SITE; ARTICLE; CELL CONTACT; CELL FUSION; CELL INTERACTION; CELL MIGRATION; CELL TRANSFER; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SIMIAN IMMUNODEFICIENCY VIRUS; SYNCYTIUM; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GLYCOPROTEINS; GLYCOSYLATION; MACACA MULATTA; MACROPHAGES; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM;

EID: 84897498327     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02785-13     Document Type: Article

References (101)

1. Doms RW, Trono D. 2000. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 14:2677-2688. http://dx.doi.org/10.1101/gad.833300.
2. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888. http://dx.doi.org/10.1126/science.280.5371.1884.
3. Puffer BA, Altamura LA, Pierson TC, Doms RW. 2004. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology 327:16-25. http://dx.doi.org/10.1016/j.virol.2004.03.016.
4. Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR. 2011. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J. Virol. 85:2397-2405. http://dx.doi.org/10.1128/JVI.02187-10.
5. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, Wolinsky SM, Gabuzda D. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. U. S. A. 103:15160-15165. http://dx.doi.org/10.1073/pnas.0605513103.
6. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD, Fox HS, Desrosiers RC, Doms RW. 2002. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J. Virol. 76:2595-2605. http://dx.doi.org/10.1128/JVI.76.6.2595-2605.2002.
7. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC. 2001. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J. Virol. 75:3903-3915. http://dx.doi.org/10.1128/JVI.75.8.3903-3915.2001.
8. Bannert N, Schenten D, Craig S, Sodroski J. 2000. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J. Virol. 74:10984-10993. http://dx.doi.org/10.1128/JVI.74.23.10984-10993.2000.
9. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D. 2002. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76:6277-6292. http://dx.doi.org/10.1128/JVI.76.12.6277-6292.2002.
10. Mori K, Rosenzweig M, Desrosiers RC. 2000. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J. Virol. 74:10852-10859. http://dx.doi.org/10.1128/JVI.74.22.10852-10859.2000.
11. Walter BL, Wehrly K, Swanstrom R, Platt E, Kabat D, Chesebro B.2005. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J. Virol. 79:4828-4837. http://dx.doi.org/10.1128/JVI.79.8.4828-4837.2005.
12. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769. http://dx.doi.org/10.1146/annurev.immunol.24.021605.090557.
13. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407. http://dx.doi.org/10.1016/j.chom.2012.09.008.
14. Burton DR, Stanfield RL, Wilson IA. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102:14943-14948. http://dx.doi.org/10.1073/pnas.0505126102.
15. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155. http://dx.doi.org/10.1038/nrmicro1819.
16. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J. 1998. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:4694-4703.
17. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
18. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, Desrosiers RC. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77:9993-10003. http://dx.doi.org/10.1128/JVI.77.18.9993-10003.2003.
19. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC.2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215. http://dx.doi.org/10.1128/JVI.78.10.5205-5215.2004.
20. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. http://dx.doi.org/10.1038/31514.
21. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
22. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. 2012. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. http://dx.doi.org/10.1038/nature11519.
23. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
24. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343. http://dx.doi.org/10.1038/nature10696.
25. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U. S. A. 102:13372-13377. http://dx.doi.org/10.1073/pnas.0505763102.
26. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103. http://dx.doi.org/10.1126/science.1213256.
27. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
28. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. 2013. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U. S. A. 110:4351-4356. http://dx.doi.org/10.1073/pnas.1217537110.
29. Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D. 2007. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 367:222-234. http://dx.doi.org/10.1016/j.virol.2007.05.029.
30. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. 1994. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J. Virol. 68:2253-2259.
31. Shioda T, Levy JA, Cheng-Mayer C. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349:167-169. http://dx.doi.org/10.1038/349167a0.
32. Stamatatos L, Wiskerchen M, Cheng-Mayer C. 1998. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res. Hum. Retroviruses 14:1129-1139. http://dx.doi.org/10.1089/aid.1998.14.1129.
33. Dunfee RL, Thomas ER, Gabuzda D. 2009. Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Retrovirology 6:69. http://dx.doi.org/10.1186/1742-4690-6-69.
34. Brown RJ, Peters PJ, Caron C, Gonzalez-Perez MP, Stones L, Ankghuambom C, Pondei K, McClure CP, Alemnji G, Taylor S, Sharp PM, Clapham PR, Ball JK. 2011. Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J. Virol. 85:6024-6037. http://dx.doi.org/10.1128/JVI.00131-11.
35. Duncan CJ, Sattentau QJ. 2011. Viral determinants of HIV-1 macrophage tropism. Viruses 3:2255-2279. http://dx.doi.org/10.3390/v3112255.
36. Toohey K, Wehrly K, Nishio J, Perryman S, Chesebro B. 1995. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology 213: 70-79. http://dx.doi.org/10.1006/viro.1995.1547.
37. Imamichi H, Igarashi T, Imamichi T, Donau OK, Endo Y, Nishimura Y, Willey RL, Suffredini AF, Lane HC, Martin MA. 2002. Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proc. Natl. Acad. Sci. U. S. A. 99:13813-13818. http://dx.doi.org/10.1073/pnas.212511599.
38. Igarashi T, Imamichi H, Brown CR, Hirsch VM, Martin MA. 2003. The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+ T cell-depleted rhesus monkeys. J. Leukoc. Biol. 74:772-780. http://dx.doi.org/10.1189/jlb.0503196.
39. Mori K, Ringler DJ, Kodama T, Desrosiers RC. 1992. Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J. Virol. 66:2067-2075.
40. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA.2000. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74:1961-1972. http://dx.doi.org/10.1128/JVI.74.4.1961-1972.2000.
41. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841. http://dx.doi.org/10.1038/nature03327.
42. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A. 2011. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 208:1419-1433. http://dx.doi.org/10.1084/jem.20110196.
43. Liu L, Cimbro R, Lusso P, Berger EA. 2011. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 108:20148-20153. http://dx.doi.org/10.1073/pnas.1104840108.
44. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477-1483. http://dx.doi.org/10.1126/science.1245625.
45. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484-1490. http://dx.doi.org/10.1126/science.1245627.
46. Marcon L, Sodroski J. 1997. High degree of sensitivity of the simian immunodeficiency virus (SIVmac) envelope glycoprotein subunit association to amino acid changes in the glycoprotein 41 ectodomain. AIDS Res. Hum. Retroviruses 13:441-447. http://dx.doi.org/10.1089/aid.1997.13.441.
47. Bixby JG, Laur O, Johnson WE, Desrosiers RC. 2010. Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res. Hum. Retroviruses 26:1115-1131. http://dx.doi.org/10.1089/aid.2010.0029.
48. Kornfeld H, Riedel N, Viglianti GA, Hirsch V, Mullins JI. 1987. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature 326:610-613. http://dx.doi.org/10.1038/326610a0.
49. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J. 2000. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J. Virol. 74:4433-4440. http://dx.doi.org/10.1128/JVI.74.9.4433-4440.2000.
50. Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B. 2009. A quantitative affinityprofiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 83:11016-11026. http://dx.doi.org/10.1128/JVI.01242-09.
51. Edinger AL, Ahuja M, Sung T, Baxter KC, Haggarty B, Doms RW, Hoxie JA. 2000. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J. Virol. 74:7922-7935. http://dx.doi.org/10.1128/JVI.74.17.7922-7935.2000.
52. Herschhorn A, Oz-Gleenberg I, Hizi A. 2008. Quantitative analysis of the interactions between HIV-1 integrase and retroviral reverse transcriptases. Biochem. J. 412:163-170. http://dx.doi.org/10.1042/BJ20071279.
53. Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB, III, Sodroski J. 2011. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 7:e1002101. http://dx.doi.org/10.1371/journal.ppat.1002101.
54. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, Mascola JR, Nabel GJ, Haynes BF, Bhattacharya T, Perelson AS, Korber BT, Hahn BH, Shaw GM. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206:1117-1134. http://dx.doi.org/10.1084/jem.20082831.
55. Strickland SL, Gray RR, Lamers SL, Burdo TH, Huenink E, Nolan DJ, Nowlin B, Alvarez X, Midkiff CC, Goodenow MM, Williams K, Salemi M. 2011. Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources. AIDS Res. Hum. Retroviruses 27:1327-1332. http://dx.doi.org/10.1089/aid.2011.0100.
56. Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M, Jr, Chertova E, Giavedoni LD, O'Connor DH, Lifson JD, Keele BF. 2013. Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J. Virol. 87:4584-4595. http://dx.doi.org/10.1128/JVI.03507-12.
57. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, Cho MW.2001. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75: 5998-6006. http://dx.doi.org/10.1128/JVI.75.13.5998-6006.2001.
58. Lue J, Hsu M, Yang D, Marx P, Chen Z, Cheng-Mayer C. 2002. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J. Virol. 76:10299-10306. http://dx.doi.org/10.1128/JVI.76.20.10299-10306.2002.
59. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684. http://dx.doi.org/10.1038/nm0698-679.
60. Wolk T, Schreiber M. 2006. N-glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195: 165-172. http://dx.doi.org/10.1007/s00430-006-0016-z.
61. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC.2004. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J. Virol. 78:1525-1539. http://dx.doi.org/10.1128/JVI.78.3.1525-1539.2004.
62. Chackerian B, Rudensey LM, Overbaugh J. 1997. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71:7719-7727.
63. Kolchinsky P, Kiprilov E, Sodroski J. 2001. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75: 2041-2050. http://dx.doi.org/10.1128/JVI.75.5.2041-2050.2001.
64. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. 2001. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75:3435-3443. http://dx.doi.org/10.1128/JVI.75.7.3435-3443.2001.
65. Li Y, Luo L, Rasool N, Kang CY. 1993. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67:584-588.
66. Land A, Braakman I. 2001. Folding of thehumanimmunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie 83:783-790. http://dx.doi.org/10.1016/S0300-9084(01)01314-1.
67. Haim H, Salas I, Sodroski J. 2013. Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. J. Virol. 87:1884-1889. http://dx.doi.org/10.1128/JVI.02765-12.
68. Groot F, Welsch S, Sattentau QJ. 2008. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111:4660-4663. http://dx.doi.org/10.1182/blood-2007-12-130070.
69. Carr JM, Hocking H, Li P, Burrell CJ. 1999. Rapid and efficient cellto-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 265:319-329. http://dx.doi.org/10.1006/viro.1999.0047.
70. Sharova N, Swingler C, Sharkey M, Stevenson M. 2005. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 24:2481-2489. http://dx.doi.org/10.1038/sj.emboj.7600707.
71. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. 2007. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J. Virol. 81:1000-1012. http://dx.doi.org/10.1128/JVI.01629-06.
72. Chen P, Hubner W, Spinelli MA, Chen BK. 2007. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 81:12582-12595. http://dx.doi.org/10.1128/JVI.00381-07.
73. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A. 2012. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8:e1002634. http://dx.doi.org/10.1371/journal.ppat.1002634.
74. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95-98. http://dx.doi.org/10.1038/nature10347.
75. Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F. 2009. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J. Virol. 83:10527-10537. http://dx.doi.org/10.1128/JVI.01235-09.
76. Ganesh L, Leung K, Lore K, Levin R, Panet A, Schwartz O, Koup RA, Nabel GJ. 2004. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J. Virol. 78:11980-11987. http://dx.doi.org/10.1128/JVI.78.21.11980-11987.2004.
77. Jolly C, Booth NJ, Neil SJ. 2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 84:12185-12199. http://dx.doi.org/10.1128/JVI.01447-10.
78. Piguet V, Steinman RM. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28:503-510. http://dx.doi.org/10.1016/j.it.2007.07.010.
79. Cavrois M, Neidleman J, Greene WC. 2008. The Achilles heel of the Trojan horse model of HIV-1 trans-infection. PLoS Pathog. 4:e1000051. http://dx.doi.org/10.1371/journal.ppat.1000051.
80. Piguet V, Sattentau Q. 2004. Dangerous liaisons at the virological synapse. J. Clin. Invest. 114:605-610. http://dx.doi.org/10.1172/JCI22812.
81. Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG. 2013. CD4+ T cells support production of simian immunodeficiency virus env antibodies that enforce CD4-dependent entry and shape tropism in vivo. J. Virol. 87:9719-9732. http://dx.doi.org/10.1128/JVI.01254-13.
82. Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G. 2011. Depletion of CD4(+) T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J. Clin. Invest. 121:4433-4445. http://dx.doi.org/10.1172/JCI46023.
83. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113. http://dx.doi.org/10.1038/nature07159.
84. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S. 2011. Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J. Virol. 85:12114-12123. http://dx.doi.org/10.1128/JVI.05297-11.
85. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 6:e1001249. http://dx.doi.org/10.1371/journal.ppat.1001249.
86. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S. 2012. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8:e1002797. http://dx.doi.org/10.1371/journal.ppat.1002797.
87. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445. http://dx.doi.org/10.1073/pnas.1101414108.
88. Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, Gorlani A, Verrips T, Lifson JD, Subramaniam S. 2013. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc. Natl. Acad. Sci. U. S. A. 110:513-518. http://dx.doi.org/10.1073/pnas.1214810110.
89. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski J. 2012. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19:893-899. http://dx.doi.org/10.1038/nsmb.2351.
90. Mao Y, Wang L, Gu C, Herschhorn A, Desormeaux A, Finzi A, Xiang SH, Sodroski JG. 2013. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 110:12438-12443. http://dx.doi.org/10.1073/pnas.1307382110.
91. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, Wang Y. 2013. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10:14. http://dx.doi.org/10.1186/1742-4690-10-14.
92. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9:301-309. http://dx.doi.org/10.1038/ni1566.
93. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O'Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J. 2009. The integrin alpha4beta7 forms a complex with cellsurface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 106:20877-20882. http://dx.doi.org/10.1073/pnas.0911796106.
94. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW. 2012. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 8:e1002686. http://dx.doi.org/10.1371/journal.ppat.1002686.
95. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers RC. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112. http://dx.doi.org/10.1126/science.2160735.
96. Clarke S, Berry N, Ham C, Alden J, Almond N, Ferguson D. 2012. Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodeficiency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques. J. Neurovirol. 18:100-112. http://dx.doi.org/10.1007/s13365-012-0084-3.
97. Rud EW, Cranage M, Yon J, Quirk J, Ogilvie L, Cook N, Webster S, Dennis M, Clarke BE. 1994. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J. Gen. Virol. 75(Part 3):529-543.
98. Choi WS, Collignon C, Thiriart C, Burns DP, Stott EJ, Kent KA, Desrosiers RC. 1994. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J. Virol. 68:5395-5402.
99. Naidu YM, Kestler HW, III, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, Daniel MD, Desrosiers RC. 1988. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J. Virol. 62:4691-4696.
100. Luciw PA, Shaw KE, Unger RE, Planelles V, Stout MW, Lackner JE, Pratt-Lowe E, Leung NJ, Banapour B, Marthas ML. 1992. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res. Hum. Retroviruses 8:395-402. http://dx.doi.org/10.1089/aid.1992.8.395.
101. Flaherty MT, Hauer DA, Mankowski JL, Zink MC, Clements JE. 1997. Molecular and biological characterization of a neurovirulent molecular clone of simian immunodeficiency virus. J. Virol. 71:5790-5798.